Lonza debuts on SGX

The pharmaceutical supplier is the first SIX Swiss-listed company to dual list in Singapore.

Lonza Group Ltd, a supplier to the pharmaceutical, healthcare and life science industries, expects to make its trading debut on the Main Board of the Singapore Exchange Securities Trading Limited at 9:00 am tomorrow, 21 October 2011 (Singapore time).

Listed on the SIX Swiss Exchange since November 1999, Lonza is the first SIX Swiss-listed company to be secondary listed by way of an introduction on the SGX-ST. Based on the closing market price of the company’s shares quoted on the SIX on 19 October 2011, Lonza has a market capitalization of approximately CHF 2,982 million. This corresponds to approximately SGD 4,183 million based on an exchange rate of CHF 1.00 to SGD 1.4028 as quoted by Bloomberg on 19 October 2011.

UBS AG, Singapore Branch acted as the issue manager for the introduction and Drew and Napier LLC acted as the solicitors to the introduction and legal advisers to the company as to Singapore law.

Lonza will be secondary listed on the SGX-ST and will not be subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realisations, and delisting.